ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience1998
Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 100 citations in OpenAlex.
- Anti-Glycolipid Antibody Examination in Five EAE Models and Theiler's Virus Model of Multiple Sclerosis: Detection of Anti-GM1, GM3, GM4, and Sulfatide Antibodies in Relapsing-Remitting EAE.International journal of molecular sciences · 2023Article
- Critical role of TLR activation in viral replication, persistence, and pathogenicity of Theiler's virus.Frontiers in immunology · 2023Review
- Single-molecule tracking of myelin basic protein during oligodendrocyte differentiation.Biological imaging · 2023Article
- Excessive Innate Immunity Steers Pathogenic Adaptive Immunity in the Development of Theiler's Virus-Induced Demyelinating Disease.International journal of molecular sciences · 2021Review
- Antibody characterization using immunosignatures.PloS one · 2020Article
- Strategies for Oligodendrocyte and Myelin Repair in Traumatic CNS Injury.Frontiers in cellular neuroscience · 2020Review
- B-1a lymphocytes promote oligodendrogenesis during brain development.Nature neuroscience · 2018Article
- Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study.Journal of visualized experiments : JoVE · 2016Article
- Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth.Journal of neuroinflammation · 2015Article
- Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases.Expert review of neurotherapeutics · 2014Review
- Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.Expert review of neurotherapeutics · 2013Review
- Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.Discovery medicine · 2013Review
- Transferrin receptor and ferritin-H are developmentally regulated in oligodendrocyte lineage cells.Neural regeneration research · 2013Article
- PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation.PloS one · 2013Article
- High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance.Analytical chemistry · 2012Article
- Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.Neurology research international · 2011Article
- Method of identifying natural antibodies for remyelination.Journal of clinical immunology · 2010Article
- Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies.Archives of neurology · 2009Review
- Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation.Clinical and experimental immunology · 2009Review
- Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins.Biotechnology journal · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We previously identified the remyelinating activity of a natural IgMkappa oligodendrocyte-reactive autoantibody (SCH94.03), using a virus-induced murine model of multiple sclerosis. We now describe a second mouse IgMkappa monoclonal antibody (mAb) (SCH79.08) raised against normal mouse spinal cord homogenate, which reacts with myelin basic protein and also promotes remyelination. Because these two mAbs recognize different oligodendrocyte antigens, several previously identified oligodendrocyte-reactive IgMkappa mAbs (O1, O4, A2B5, and HNK-1), each with distinct antigen specificities, were evaluated and found to promote remyelination. In contrast, IgMkappa mAbs that did not bind to oligodendrocytes showed no remyelination. One of these, CH12 IgMkappa mAb, which shares variable region cDNA sequences with SCH94.03 except for amino acid differences in the complementarity-determining region 3 in both heavy and light chains, did not bind to oligodendrocytes and did not promote remyelination. The fact that multiple oligodendrocyte-reactive antibodies with distinct antigen reactivities induce remyelination argues against direct activation by a unique cell surface receptor. These findings are most consistent with the hypothesis that the binding of mAbs to oligodendrocytes in the lesions induces myelin repair via indirect immune effector mechanisms initiated by the mu-chain. Importantly, these studies indicate that oligodendrocyte-reactive natural autoantibodies may provide a powerful and novel therapeutic means to induce remyelination in multiple sclerosis patients.
Indexed as
Identifiers
9742140PMC6793011W2123660829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.